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heparin and indomethacin in the prevention of deep-vein
thrombosis after total knee arthroplasty in Asian patients.
METHODS: One hundred ﬁfty patients undergoing 
total knee arthroplasty were randomly divided into 
three groups. Group I (the control group) consisted of 51
patients receiving no prophylaxis with an anticoagulant.
Group II consisted of 50 patients receiving the low mol-
ecular weight heparin fraxiparine, and group III consisted
of 49 patients receiving indomethacin. Bilateral ascend-
ing venograms were performed preoperatively and at ﬁve
to seven days postoperatively. A third venogram was 
performed at 3 months in patients who had had a deep
vein thrombosis. RESULTS: The prevalence of deep vein
thrombosis was 71% for the control group versus 50%
for the fraxiparine group (p = 0.042), and 45% for the
indomethacin group (p = 0.011). Deep vein thromboses
were symptomatic in only 28% of the cases, and there
was no pulmonary embolism. CONCLUSIONS:
Fraxiparine and indomethacin signiﬁcantly lowered the
prevalence of deep-vein thrombosis after total knee
arthroplasty as compared with the control. Prophylaxis
for deep vein thrombosis in the Asian population ap-
peared to be warranted. Furthermore, deep-vein throm-
bosis in the calf showed a tendency to improve with 
time.
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ANGINA OR NON-Q-WAVE MYOCARDIAL
INFARCTION
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Mora V,Vaquerizo B, Martínez-Diago V,Aguar P, Orriach MD,
Salvador A
Dr. Peset Hospital,Valencia,Valencia, Spain
OBJECTIVE: We have tried to know the prognostic value
of Troponin T levels (TnT) in patients (p) with a clinical
presentation suggestive of angina, which induced hospi-
tal admission. METHODS: We have followed up 241
consecutive p, 162 male and 79 female, mean age 67.4y.
(range 18 to 89) who initially did not develop a Q-wave
acute myocardial infarction. RESULTS: TnT levels were
higher than 0.1ng/ml in 90p (37%, group TnT+) and
lower than 0.1 in the 63% (group TnT-). Both groups
had comparable age and proportion of women (69 vs. 67
years and 35% vs. 32%, respectively). Every non-Q-wave
infarction p (a = 27) had high levels of TnT. Several
outcome events [death (Dh), heart failure (HF), acute
myocardial infarction (AMI) or need of revascularization
(Rev)] were recalled either by phone or personal interview
three months after the initial clinical episode. Relative
risks and 95% conﬁdence limits of TnT+ for grouped
events considering all the patients was 2.24 for Dh or HF;
2.42 for Dh or AMI; 2.52 for Dh or HF or AMI and 2.14
for Dh, HF, AMI or Rev., and excluding those with non-
Q-wave infarction was 2.66 for Dh or HF; 3.2 for Dh or
AMI; 2.8 for Dh or HF or AMI and 2.66 for Dh, HF,
AMI or Rev. CONCLUSIONS: Patients with chest pain
who require hospitalization due to an admission diagno-
sis of unstable angina or non-Q-wave myocardial infarc-
tion have a different three month outcome depending on
the troponin levels in the ﬁrst 24 hours. Levels higher
than 0.1ng/ml almost triplicate the risk of major events
even when patients with non-Q-wave infarction are
excluded.
PCV6
ASSESSMENT OF THE QUALITY OF DRUG
TREATMENT IN ESSENTIAL HYPERTENSION IN
SLOVAK REPUBLIC
Szalayova A, Dubrava M, Kriska M
Comenius University, Bratislava, Slovak Republic
OBJECTIVES: To evaluate the possibility to use data
from insurance companies for assessing the quality of
drug treatment and to assess the prescribing patterns 
for essential hypertension in Slovak Republic (SR).
METHODS: From population of 5 selected counties in
Slovak Republic insured in General Sickness Fund
(509,241 people, almost 10% of population of SR),
81,870 patients were treated for essential hypertension in
2001. Antihypertensive treatment of those patients was
assessed according to the quantity and quality of pre-
scribed drugs. A set of non-speciﬁc and disease-speciﬁc
markers of rationality was developed and used for this
purpose. RESULTS: Average number of daily deﬁned
doses (DDD) for patient was 3537 times a year. The 
most common prescribed antihypertensive group were
angiotensin-converting enzyme inhibitors (126,5DDD on
patient and year). A total of 35% of patients had pre-
scribed less than 150DDDs for a year and almost 10%
had more than 450DDDs from one group of antihy-
pertensives. Great differences between counties were
observed. CONCLUSIONS: Unique characteristic of
Slovak system of issuing prescriptions that require enter-
ing the diagnosis, allows using data from prescriptions for
the quality assessment of drug treatment. The results from
our analysis show low compliance of physicians with
existing guidelines and the need for increased activities
for improving the quality of drug treatment.
PCV7
MITRAL REPAIR CAN BE SAFELY PERFORMED
IN CASES OF INCREASED COMPLEXITY
Sonnad SS1, Badhwar V2, Smolens IA2, Bolling SF2
1University of Pennsylvania, Philadelphia, PA, USA; 2University
of Michigan, Ann Arbor, MI, USA
OBJECTIVES: The beneﬁts of repair over replacement
for mitral valve dysfunction are well established.
However, despite growing experience with reparative
surgery, concerns over patients with increased comor-
bidities or requiring concomitant cardiac procedures may
still lead surgeons to elect to perform a more familiar
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mitral replacement. To assess how experience may impact
the efﬁcacy of mitral repair on patients with increasing
complexity, we examined 941 consecutive patients who
underwent mitral valve repair from July 1992 to January
2000. METHODS: All patients underwent primary
mitral repair for regurgitation. Of the 941 patients, 750
had their operations between July 1992 and December
1998 (A), and 191 between January 1999 and January
2000 (B). Outcomes were analyzed for incidences of STS
co-morbid criteria and concomitant cardiac procedures
(valvular, arch, or CABG) performed during the study
periods. RESULTS: For the 941 patients, 530 (56%) were
male, patient age was 62 ± 13.3 years (range 20–88).
Group A included 204/750 with comorbidities (27.2%)
vs. 176/191 (92%) in Group B (p < 0.0001). Overall 
incidence of concomitant procedures in the 2 groups was
similar [58% A, 57% B (p = NS)]. Cross clamp times were
reduced from 104.9 ± 12.5 min in Group A to 84.9 ± 10.4
min in Group B (p < 0.0001). There were no differences
in atrial ﬁbrillation between groups (27.6% A, 28.3% B).
There were a total of 53 30-day mortalities (5.6%), with
a trend towards reduced mortality in Group B [6.1%
Group A, 3.7% Group B (p = 0.19)]. Average LOS
decreased from 12.2 ± 14.9 days in Group A to 8.7 ± 8.5
days in Group B (p = 0.02). CONCLUSIONS: Mitral
valve repair remains a safe and effective treatment for
patients with mitral regurgitation including those with
comorbid conditions and those requiring concomitant
cardiac procedures. As experience is gained with repara-
tive techniques, surgeons may be more willing to safely
apply them to an increasingly complex patient 
population.
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CHOICE OF FIRST-LINE TREATMENT FOR
HYPERTENSION IN THE UK: DOES CURRENT
PRIMARY CARE PRACTICE REFLECT BRITISH
GUIDELINES?
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OBJECTIVES: This study sets out to explore the adher-
ence to British Hypertension Guidelines in choosing ﬁrst-
line treatment for blood pressure by general practitioners
(GPs) in the UK. These currently recommend thiazide
diuretics as the preferred choice and beta-blockers as 
an alternative initial treatment for most patients.
METHODS: The data on choice of blood pressure treat-
ment recorded at ﬁrst diagnosis of hypertension were
obtained from a UK GP computer database, IMS Disease
Analyzer—Mediplus. The records covered the 1-year
period March 2002 to February 2003. The database
holds the records of 564GPs and 948,958 registered
patients. RESULTS: Of 8,540 patients with at least three
months history on the database and a new diagnosis of
hypertension within the year of analysis, initial treatment
was as follows: 36.5% thiazide diuretic; 22.4% beta-
blocker; 17.8% ACE inhibitor; 10.1% calcium channel
blocker; 4.0% angiotensin-2-receptor antagonist; 2.1%
alpha-blocker. Of those, 16.4% were not started imme-
diately on antihypertensive therapy. Of those that did,
4.6% received ﬁrst treatment as a combination of two
drugs (hence the total ﬁgures do not add up to 100%).
CONCLUSIONS: This study suggests that ﬁrst-line treat-
ment is often using a drug that is not in accord with
current National policy as only 58.9% were started on
recommended ﬁrst-line therapy. Choices from other drug
classes tend to be more expensive, and there is less evi-
dence of beneﬁt. In particular the 4.6% starting treatment
with combination therapy appears at odds with the policy
to start with a single agent. Co-morbidity such as diabetes
or bladder outﬂow obstruction may explain the choice of
other agents; for example angiotensin-inhibiting drugs in
diabetes, but the prevalence of these conditions is not suf-
ﬁcient to explain this variation from the guidelines. This
choice of drugs may reﬂect heavy marketing of these
newer products rather than evidence-based medicine.
PCV9
THE USE OF SHORT MESSAGES TO THE
PATIENT’S MOBILE PHONE AS HEALTH CARE
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OBJECTIVES: To demonstrate the feasibility and pa-
tient acceptance of a health care intervention using 
the patient’s mobile phone (HTA-Alert Study), and to
describe the pattern of use of this tool in the usual clini-
cal practice (INFONET Program) in hypertensive (HT)
patients. METHODS: 1) HTA-Alert Study: 20 primary
care investigators were randomized to Control (CG) or
Intervention (IG) group. Investigators of IG registered
their patients in a free SMS service. These patients
received two short-messages per week, during 24 weeks.
Messages addressed issues related with compliance and
health habits. 2) INFONET Program: 40 Hypertension
Units (UHTA) asked patients to enter periodically blood
pressure into a private web site, where physicians had
access to data. Physicians were asked to send free-text
SMSs to the patient mobile phone via web application at
their own convenience. RESULTS: 1) HTA-Alert: 33
Patients CG and 34IG were studied. There was a relevant
reduction in weight (from 80.47 ± 9.76kg to 76.84 ±
8.92; p < 0.001) in the IG. Hypertension was reduced in
